Log In
Print this Print this

ALS-2200, VX-135

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionNucleotide HCV NS5B polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionHCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV infection; Treat HCV genotype 1 infection; Treat HCV infection; Treat non-cirrhotic, treatment-naïve patients with chronic HCV genotype 1 infection
Regulatory Designation


Vertex Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today